357 related articles for article (PubMed ID: 10964310)
1. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation.
Jungehülsing M; Scheidhauer K; Damm M; Pietrzyk U; Eckel H; Schicha H; Stennert E
Otolaryngol Head Neck Surg; 2000 Sep; 123(3):294-301. PubMed ID: 10964310
[TBL] [Abstract][Full Text] [Related]
2. Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study.
Johansen J; Eigtved A; Buchwald C; Theilgaard SA; Hansen HS
Laryngoscope; 2002 Nov; 112(11):2009-14. PubMed ID: 12439171
[TBL] [Abstract][Full Text] [Related]
3. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose.
Greven KM; Keyes JW; Williams DW; McGuirt WF; Joyce WT
Cancer; 1999 Jul; 86(1):114-8. PubMed ID: 10391570
[TBL] [Abstract][Full Text] [Related]
4. [F-18 FDG PET for detection of occult primary tumor in patients with lymphatic metastases of the neck region].
Bohuslavizki KH; Klutmann S; Sonnemann U; Thoms J; Kröger S; Werner JA; Mester J; Clausen M
Laryngorhinootologie; 1999 Aug; 78(8):445-9. PubMed ID: 10488465
[TBL] [Abstract][Full Text] [Related]
5. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors.
AAssar OS; Fischbein NJ; Caputo GR; Kaplan MJ; Price DC; Singer MI; Dillon WP; Hawkins RA
Radiology; 1999 Jan; 210(1):177-81. PubMed ID: 9885604
[TBL] [Abstract][Full Text] [Related]
6. ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor.
Zhao K; Luo XM; Zhou SH; Liu JH; Yan SX; Lu ZJ; Yang SY; Lin LL; Dong MJ
Cancer Biother Radiopharm; 2012 Dec; 27(10):685-93. PubMed ID: 22834634
[TBL] [Abstract][Full Text] [Related]
7. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
8. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.
Regelink G; Brouwer J; de Bree R; Pruim J; van der Laan BF; Vaalburg W; Hoekstra OS; Comans EF; Vissink A; Leemans CR; Roodenburg JL
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1024-30. PubMed ID: 12173016
[TBL] [Abstract][Full Text] [Related]
9. Role of 18F-FDG PET in detecting primary site in the patient with primary unknown carcinoma.
Yabuki K; Tsukuda M; Horiuchi C; Taguchi T; Nishimura G
Eur Arch Otorhinolaryngol; 2010 Nov; 267(11):1785-92. PubMed ID: 20814690
[TBL] [Abstract][Full Text] [Related]
10.
Cheol Park G; Roh JL; Cho KJ; Seung Kim J; Hyeon Jin M; Choi SH; Yuhl Nam S; Yoon Kim S
Int J Cancer; 2017 Mar; 140(6):1405-1412. PubMed ID: 27943271
[TBL] [Abstract][Full Text] [Related]
11. Cervical lymph node metastases of squamous cell carcinoma of unknown origin: the diagnostic value of FDG PET/CT and clinical outcome.
Dale E; Moan JM; Osnes TA; Bogsrud TV
Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):1015-1019. PubMed ID: 27671150
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site.
Cianchetti M; Mancuso AA; Amdur RJ; Werning JW; Kirwan J; Morris CG; Mendenhall WM
Laryngoscope; 2009 Dec; 119(12):2348-54. PubMed ID: 19718744
[TBL] [Abstract][Full Text] [Related]
13. Unknown primary detected by FDG-PET. A review of the present indications of FDG-PET in head and neck cancers.
Sheikholeslam-zadeh R; Choufani G; Goldman S; Hassid S
Acta Otorhinolaryngol Belg; 2002; 56(1):77-82. PubMed ID: 11894635
[TBL] [Abstract][Full Text] [Related]
14. Lymph node metastasis of squamous cell carcinoma from an unknown primary: impact of positron emission tomography.
Stoeckli SJ; Mosna-Firlejczyk K; Goerres GW
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):411-6. PubMed ID: 12634970
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of diffusion-weighted imaging and
Noij DP; Martens RM; Zwezerijnen B; Koopman T; de Bree R; Hoekstra OS; de Graaf P; Castelijns JA
Eur J Radiol; 2018 Oct; 107():20-25. PubMed ID: 30292267
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study.
Johansen J; Buus S; Loft A; Keiding S; Overgaard M; Hansen HS; Grau C; Bundgaard T; Kirkegaard J; Overgaard J
Head Neck; 2008 Apr; 30(4):471-8. PubMed ID: 18023031
[TBL] [Abstract][Full Text] [Related]
17. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
18. Use of a coincidence gamma camera to detect primary tumor with 18fluoro-2-deoxy-glucose in cervical lymph node metastases from an unknown origin.
Périé S; Talbot JN; Monceaux G; Grahek D; Kerrou K; Montravers F; St Guily JL
Ann Otol Rhinol Laryngol; 2000 Aug; 109(8 Pt 1):755-60. PubMed ID: 10961809
[TBL] [Abstract][Full Text] [Related]
19. The real additional value of FDG-PET in detecting the occult primary tumour in patients with cervical lymph node metastases of unknown primary tumour.
de Bree R
Eur Arch Otorhinolaryngol; 2010 Nov; 267(11):1653-5. PubMed ID: 20827553
[No Abstract] [Full Text] [Related]
20. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
